Mirum Pharmaceuticals, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Investors need quarterly results to track if the company is growing revenue and managing costs.
Shows how the company performed in the three months ending June 30, 2026.
Shareholders voted on company leadership and governance decisions affecting your ownership.
Company raises cash but existing shareholders may be diluted if notes convert to stock.
Investors need quarterly results to track if the company is growing revenue and managing costs.
Shows how the company performed in the three months ending March 31, 2026.
Positive drug trial results bring the medicine closer to approval and potential future revenue.
Stocky reads Mirum Pharmaceuticals, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Mirum Pharmaceuticals, Inc.'s most recent tracked filing was a 10-Q on 5 Aug 2026: Reports second quarter 2026 financial results.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.